Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

PURPOSE: Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor–positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics is still unknown. We evaluated and compared changes of gene e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Bergamino, Milana A., Morani, Gabriele, Parker, Joel, Schuster, Eugene F., Leal, Mariana F., López-Knowles, Elena, Tovey, Holly, Bliss, Judith M., Robertson, John F.R., Smith, Ian E., Dowsett, Mitch, Cheang, Maggie C.U.
Formato: Artigo
Idioma:Inglês
Publicado em: American Association for Cancer Research 2022
Assuntos:
Translational Cancer Mechanisms and Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612503/
https://ncbi.nlm.nih.gov/pubmed/34965950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-2718
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados